Critical care
Genetic IL-6 receptor blockade links to lower sepsis risk
Open access · cc by · source: Europe PMC
Mendelian randomisation treating IL6R variants as a natural experiment for receptor blockade found lower odds of sepsis (OR 0.80) and critical-care sepsis (OR 0.48) in UK Biobank, with a similar-sized protective association for severe COVID-19.
Study at a glance
- Design
- Mendelian randomisation — IL6R genetic instruments as proxies for lifelong IL-6 receptor blockade; UK Biobank primary
- N
- N=486484 · UK Biobank ≈486,484 adults including 11,643 sepsis cases; secondary FinnGen and COVID-19 HGI
- Population
- UK Biobank adults (with secondary European/COVID genetics cohorts)
- Outcome
- Odds of sepsis (and severe sepsis / severe COVID-19 phenotypes)
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Genetically proxied IL6R blockade associated with lower odds of sepsis (OR 0.80, 95% CI 0.66–0.96) and stronger associations for more severe phenotypes such as critical-care admission with sepsis (OR 0.48). A protective association of similar magnitude was confirmed for severe COVID-19 (OR 0.69), where IL-6 blockade is already recommended in critical illness.
Methodology
Authors used Mendelian randomisation with IL6R genetic instruments as proxies for lifelong IL-6 receptor blockade (the pharmacology target of drugs such as tocilizumab). Primary analyses used UK Biobank (~486k adults, 11,643 with sepsis), with secondary cohorts including FinnGen and COVID-19 Host Genetics Initiative data.
Limitations
MR estimates lifelong genetic exposure, not a same-day ICU tocilizumab RCT for bacterial sepsis. Some secondary critical-care survival intervals are wide and compatible with no effect. Results support a therapeutic hypothesis and trial priority — they do not license off-label IL6RA use for every sepsis case.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Blood leukocyte transcriptomes split ICU pneumonia sepsis into SRS1 vs SRS2 with different early mortality.
In prospective UK ICU adults with community-acquired pneumonia sepsis, unsupervised transcriptomics defined SRS1 (~41%) as an immunosuppressed state with higher 14-day mortality than SRS2 (discovery HR 2.4; validation HR 2.8), classifiable with a seven-gene set.
Scope note — different question — population genetic proxies for IL6R blockade, not ICU transcriptomic subtypes
Limits the claim's scope: a different population, assay, or outcome.
Genetically proxied IL6R blockade associates with lower sepsis risk and severity.
Mendelian randomisation treating IL6R variants as lifelong proxies for receptor blockade found lower odds of sepsis in UK Biobank (OR 0.80) and stronger associations for critical-care sepsis phenotypes (e.g., OR 0.48), with a similar-sized protective association for severe COVID-19 where IL-6 blockade is already recommended.
Evidence for the claim as stated.
SRS classes describe acute ICU transcriptomic states after pneumonia sepsis; IL6R MR estimates lifelong pathway effects on sepsis risk across a volunteer biobank. Both can be true without being the same assay or the same treatment decision.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
SRS classes describe acute ICU transcriptomic states after pneumonia sepsis; IL6R MR estimates lifelong pathway effects on sepsis risk across a volunteer biobank. Both can be true without being the same assay or the same treatment decision.
Related papers in this topic
Same topic cluster — not a recommendation engine.